Combo I-O plus chemotherapy

Chemotherapy has historically been considered immune-suppressive. The recent success of immune checkpoint inhibitors (ICI) has renewed interest in immunotherapies, and in combining them with chemotherapy to achieve additive or synergistic clinical activity [1,2]. Dr Luis Paz-Ares (Complutense University of Madrid, Spain) gave an overview about the combination of I-O and chemotherapy. The data of previous phase 1 studies evaluating front-line therapy of anti-PD-L1 or anti-PD1 agents in combination with chemotherapy were “not overwhelming”, Dr Paz-Ares mentioned [3]. “The response rates were in the range of 50%.” However, further research showed some more positive results. For example, the open-label Keynote-021 suggests that combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC [4]. Subsequently, the Keynote-189 trial showed that in patie...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 25 June, 201915 March, 2021